Loading...
Ongoing 5-year+ survival after multiple metastasectomies, followed by CAPOX plus bevacizumab, for metastatic colorectal cancer
BACKGROUND: Advancements in chemotherapy for metastatic colorectal cancer (mCRC) have improved long-term outcomes, and median survival currently exceeds 30 months. The recommended treatment for mCRC is multidisciplinary, including a combination of surgical resection and chemotherapy. In this study,...
Na minha lista:
| Udgivet i: | Surg Case Rep |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer Berlin Heidelberg
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7316900/ https://ncbi.nlm.nih.gov/pubmed/32588352 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40792-020-00913-x |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|